Brief: Lipigon Pharmaceuticals Aims To Reduce Cost Base By Two-Thirds
16/02/2026 12:56
Feb 16 (Reuters) - Lipigon Pharmaceuticals AB LPGO.ST: DECIDED ON COST-CUTTING MEASURES AIMED AT REDUCING COST BASE BY ABOUT 65% EVALUATION OF STRATEGIC ALTERNATIVES CONTINUES IF STRATEGIC REVIEW DOES NOT RESULT IN SATISFACTORY OUTCOME, BOARD MAY NEED TO FILE FOR BANKRUPTCY COST-SAVING PROGRAM IS EXPECTED TO REACH FULL EFFECT FROM Q4 2026 Source text: ID:nBQN7d9M1S Further company coverage: LPGO.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Lipigon Pharmaceuticals AB
See all newsBrief: Nasdaq To Delist Lipigon Pharmaceuticals From First North Growth Market
Brief: Lipigon Expected To Be Removed From Trading On Nasdaq Stockholm On May 18
Brief: Lipigon Proposes To Delist Company From Nasdaq First NGM
Brief: Lipigon Pharmaceuticals Oct-Dec Oper Loss At SEK 7.2 Mln
Brief: Lipigon Pharmaceuticals Aims To Reduce Cost Base By Two-Thirds